AbCellera BiologicsABCL +10.81%59 Quick Ratio is 13.89 as of Mar. 2026, which is 49% above its 10-year median of 9.34. GuruFocus rates ABCL with a GF Score™ of 59/100 and a GF Value™ of $5.62 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, AbCellera Biologics ranks better than 85.45% on this metric.
AbCellera Biologics has a quick ratio of 13.89. It generally indicates good short-term financial strength.
The historical rank and industry rank for AbCellera Biologics's Quick Ratio or its related term are showing as below:
ABCL'
s Quick Ratio Range Over the Past 10 Years
Min: 1.58 Med: 9.34 Max: 16.19
Current: 13.89
During the past 8 years, AbCellera Biologics's highest Quick Ratio was 16.19. The lowest was 1.58. And the median was 9.34.
ABCL's Quick Ratio is ranked better than 85.45% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs ABCL: 13.89
AbCellera Biologics (NAS:ABCL) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
AbCellera Biologics Quick Ratio Related Terms
AbCellera Biologics Quick Ratio Historical Data
* Premium members only.
The historical data trend for AbCellera Biologics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AbCellera Biologics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
AbCellera Biologics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics (ABCL) has a Quick Ratio of 13.89 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on AbCellera Biologics and its competitors. This is 49% above median its historical median of 9.34. Over the past decade, AbCellera Biologics' Quick Ratio has ranged from 1.58 to 16.19. According to the industry distribution chart, AbCellera Biologics ranks #206 out of 1416 companies in the Biotechnology industry, placing it in the top 14.5%.
Is AbCellera Biologics' Quick Ratio too high?
AbCellera Biologics' current Quick Ratio of 13.89 is 49% above median its 10-year median of 9.34. Over the past 10 years, this metric has ranged from a low of 1.58 to a high of 16.19. The Biotechnology industry median Quick Ratio is 3.60. AbCellera Biologics' value of 13.89 is 285.8% above this industry median. Based on the distribution chart, AbCellera Biologics ranks #206 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Quick Ratio compare to SRPT and RAPP?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #206 out of 1416 companies for Quick Ratio. This places AbCellera Biologics in the top 15% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. AbCellera Biologics' value of 13.89 is 285.8% above this benchmark. Historically, AbCellera Biologics' own Quick Ratio has ranged from 1.58 to 16.19 over the past decade. While the company's 10-year median is 9.34 vs. the industry median of 3.60, AbCellera Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbCellera Biologics's current Quick Ratio of 13.89 is 285.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on AbCellera Biologics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current Quick Ratio is 13.89, which is 49% above median its own 10-year median of 9.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.62, compared to a current price of $7.38 — trading 31.3% above its estimated fair value. The current Quick Ratio is 13.89, which is 49% above median its 10-year median of 9.34 and 285.8% above the Biotechnology industry median of 3.60. AbCellera Biologics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Quick Ratio is 13.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $7.38 is trading 31.3% above its estimated GF Value™ of $5.62.
GuruFocus considers AbCellera Biologics to be Significantly Overvalued.
Key valuation signals for ABCL:
Quick Ratio: 13.89 (49% above median its 10-year median of 9.34)
GF Value™: $5.62 vs. price of $7.38 (31.3% above fair value)
Industry Position: 285.8% above the Biotechnology median (#206 of 1416)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score
Get the complete analysis for ABCL
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 
